GT Biopharma to be Added to the Russell 2000® Index
GT Biopharma, Inc. (NASDAQ: GTBP) announced its inclusion in the Russell 2000 Index, effective June 28, 2021. This milestone reflects the company's progress in developing its TriKE™ NK cell engager technology. CEO Anthony J. Cataldo emphasized the importance of this recognition for enhancing visibility and growth potential. The Russell 2000 Index is significant for institutional investors, with approximately $9 trillion in assets benchmarked against Russell's U.S. indexes. The inclusion is expected to attract broader investment interest and support GT Biopharma's long-term objectives.
- Inclusion in the Russell 2000 Index enhances visibility and credibility.
- Reflects progress in commercializing TriKE™ NK cell engager technology.
- Potential to attract new investors due to increased recognition.
- None.
BEVERLY HILLS, Calif., June 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.
"Our inclusion in the Russell index is an important milestone for us as it reflects the continued progress we are making to develop and commercialize our first-in-class therapeutics. We welcome the enhanced visibility of our long-term growth potential and look forward to sharing our future milestones with a broader investment community," said Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership in the small-cap Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000Ò Index.
Russell's U.S. indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
For more information about the Russell U.S. Indexes and the Russell Indexes reconstitution, visit the FTSE Russell website.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology. For more information, please visit gtbiopharma.com.
Investor Contact: Brendan Payne Client Lead Stern Investor Relations, Inc. 212-362-1200
| Investor and Media Relations Contact: David Castaneda 414-351-9758
|
View original content to download multimedia:http://www.prnewswire.com/news-releases/gt-biopharma-to-be-added-to-the-russell-2000-index-301307508.html
SOURCE GT Biopharma, Inc.
FAQ
When will GT Biopharma be added to the Russell 2000 Index?
What does the inclusion in the Russell 2000 Index mean for GT Biopharma?
How does the Russell 2000 Index impact investors?